Moleculin Biotech, Inc. — Director's Dealing 2025

Nov 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2025-11-04

Reporting Person: Foster Jonathan P. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-04	Common Stock	M	20625	—	Acquired	308212	Direct
2025-11-04	Common Stock	M	5023	$0.4970	Disposed	303189	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-04	Restricted Stock Units	$	M	20625	Disposed		Common Stock (20625)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Shares withheld for payment of taxes upon vesting of restricted stock unit awards.

F3: On November 4, 2024, the reporting person was granted 82,500 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.